Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients.

This study evaluated epidemiologic and immune factors associated with pathologic complete response (pCR), breast cancer-specific survival (BCSS) and disease-free survival (DFS) outcomes in inflammatory (IBC) and locally advanced breast cancer (LABC) patients. Tumor-infiltrating lymphocytes (TILs) and CD20+ B-cell frequencies (CD20+), and PD-L1 expression on tumor (PD-L1+carcinoma cells) and immune (PD-L1+TILs) cells were analyzed by immunohistochemistry along with clinicopathologic factors as modifiers of pCR and outcomes in 221 IBC and 162 LABC patients. Analysis included Kaplan-Meier curves and Cox proportional hazard models. IBC and LABC display similar levels of TILs, CD20+, and combined CD20+ and PD-L1+TILs (CD20+PD-L1+TILs), while LABC contained more PD-L1+TILs and PD-L1+ carcinoma cells. Absence of lymphovascular involvement, high TILs, PD-L1+ carcinoma cells, and combined CD20+ and PD-L1+ carcinoma cells correlated with pCR in IBC and LABC patients. High PD-L1+TILs correlated with pCR only in LABC; less lymph node involvement at diagnosis, CD20+ and CD20+PD-L1+TILs correlated with pCR only in IBC (P < 0.04, all comparisons). Achievement of pCR in IBC and LABC patients correlated with BCSS and DFS (P < 0.02). In multivariate analyses, pCR remained an independent prognostic factor of improved DFS in IBC and LABC patients, but of BCSS in only LABC. CD20+PD-L1+TILs remained an independent prognostic factor of improved DFS and BCSS only in IBC. CD20+PD-L1+TILs are an independent prognostic biomarker of improved outcomes in IBC, but not LABC. Selecting IBC patients by CD20 and PD-L1 status could stratify patients and potentially identify those in whom activating CD20 agents and anti-PD-1/PD-L1 therapy could be explored.

Arias-Pulido H ，Cimino-Mathews AM ，Chaher N ，Qualls CR ，Joste N ，Colpaert C ，Marotti JD ，Chamberlin MD ，Foisey MG ，Prossnitz ER ，Emens LA ，Fiering S ... -  《-》

The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.

Arias-Pulido H ，Cimino-Mathews A ，Chaher N ，Qualls C ，Joste N ，Colpaert C ，Marotti JD ，Foisey M ，Prossnitz ER ，Emens LA ，Fiering S ... -  《-》

Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.

Fernandez SV ，MacFarlane AW 4th ，Jillab M ，Arisi MF ，Yearley J ，Annamalai L ，Gong Y ，Cai KQ ，Alpaugh RK ，Cristofanilli M ，Campbell KS ... -  《-》

Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.

Van Berckelaer C ，Rypens C ，van Dam P ，Pouillon L ，Parizel M ，Schats KA ，Kockx M ，Tjalma WAA ，Vermeulen P ，van Laere S ，Bertucci F ，Colpaert C ，Dirix L ... -  《-》

Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC).

Gong Y ，Nagarathinam R ，Arisi MF ，Gerratana L ，Winn JS ，Slifker M ，Pei J ，Cai KQ ，Hasse Z ，Obeid E ，Noriega J ，Sebastiano C ，Ross E ，Alpaugh K ，Cristofanilli M ，Fernandez SV ... -  《INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES》